Financial Data and Key Metrics Changes - As of December 31, 2025, the company's cash position was approximately $318.1 million, significantly increased from approximately $151.5 million as of December 31, 2024 [29] - Revenue for the fourth quarter of 2025 was $0, down from approximately $11.1 million for the same period in 2024, and full-year revenue for 2025 was also $0 compared to approximately $22.3 million in 2024 [29][30] - Total operating expenses for Q4 2025 were approximately $29.2 million, up from approximately $18.8 million in Q4 2024, and full-year operating expenses for 2025 were approximately $108.1 million compared to approximately $64.8 million in 2024 [30][31] - Net loss for Q4 2025 was approximately $30.2 million, compared to a net loss of approximately $7.1 million in Q4 2024, and the full-year net loss for 2025 was approximately $105 million compared to approximately $40.5 million in 2024 [31] Business Line Data and Key Metrics Changes - The company is focused on advancing Deramiocel toward potential approval for Duchenne muscular dystrophy (DMD) in the U.S., with a Biologics License Application (BLA) under review by the FDA [5][19] - The HOPE-3 trial results indicated a 91% slowing of disease progression in evaluable patients, with statistically significant results in patients with cardiomyopathy [10][11] - The company aims to position Deramiocel to treat as many eligible patients as possible, with a focus on both skeletal and cardiac disease manifestations of DMD [6][7] Market Data and Key Metrics Changes - The FDA has assigned a PDUFA target action date of August 22, 2026, for the review of the BLA for Deramiocel [5][19] - The company is preparing for a potential commercial launch and has completed its FDA pre-license inspection for its manufacturing facility [20][21] - The current manufacturing facility can support approximately 250 patients per year, with plans to expand capacity to accommodate up to 2,500 patients annually by late 2027 [21] Company Strategy and Development Direction - The company is building an infrastructure to support the launch and commercialization of Deramiocel while expanding its pipeline to treat other indications [8][22] - The focus is on executing a disciplined approach to commercialization, including market access, reimbursement planning, and physician education [22] - The company is also exploring expansion into other diseases, initially focusing on Becker muscular dystrophy [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the data supporting Deramiocel's potential benefit in treating DMD, emphasizing the importance of addressing both skeletal and cardiac aspects of the disease [18] - The company is optimistic about its financial position, with sufficient capital to support operations into the fourth quarter of 2027 [27] - Management highlighted the importance of early intervention in DMD treatment and the potential for Deramiocel to be used in younger patients [75] Other Important Information - The company completed a public offering in December 2025, resulting in net proceeds of approximately $162 million [29] - Capricor's common stock was approved for uplisting to the Nasdaq Global Select Market, enhancing visibility within the institutional investment community [28] Q&A Session Summary Question: Anticipation of Ad Comm and Commercial Prep for Deramiocel Approval - Management indicated uncertainty regarding an Ad Comm but expressed confidence in the strength of the HOPE-3 data regardless of whether an Ad Comm occurs [34][35] Question: Labeling Discussions and Expectations - Management noted that labeling discussions have not yet occurred but believes the data supports a label for both DMD and cardiomyopathy [38][52] Question: Cohorts of HOPE-3 Trial and FDA Considerations - Management clarified that the FDA considers Cohort A and Cohort B as one trial and expressed confidence in the statistical significance of Cohort B [44][45] Question: Manufacturing Capacity and Expansion Plans - Management confirmed plans to expand manufacturing capacity to accommodate more patients and emphasized the importance of regulatory compliance [58][70] Question: Early Intervention and Treatment of DMD - Management highlighted the importance of early intervention and the potential for Deramiocel to be used in younger patients, while acknowledging the challenges of obtaining a prevention label [75] Question: European Rights Deal Status - Management indicated that negotiations with NS Pharma for European rights are ongoing and will be prioritized following the PDUFA date [77]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents and marketable securities totaled approximately $318.1 million, a significant increase from approximately $151.5 million as of December 31, 2024 [26] - Revenue for the fourth quarter of 2025 was $0, compared to approximately $11.1 million for the same period in 2024, and full-year revenue for 2025 was also $0, down from approximately $22.3 million in 2024 [26][27] - Total operating expenses for Q4 2025 were approximately $29.2 million, up from approximately $18.8 million in Q4 2024, and full-year operating expenses for 2025 were approximately $108.1 million, compared to approximately $64.8 million in 2024 [27][28] - Net loss for Q4 2025 was approximately $30.2 million, compared to a net loss of approximately $7.1 million in Q4 2024, and the full-year net loss for 2025 was approximately $105 million, up from approximately $40.5 million in 2024 [28][29] Business Line Data and Key Metrics Changes - The company is focused on advancing Deramiocel toward potential approval for Duchenne muscular dystrophy (DMD) in the U.S., with a Biologics License Application (BLA) under review by the FDA [5][6] - The HOPE-3 trial, a pivotal phase 3 study, enrolled 106 patients and met its primary efficacy endpoint, showing a 91% slowing of disease progression in evaluable patients [9][10] - The company aims to position Deramiocel to treat as many eligible patients as possible, with a focus on both skeletal and cardiac disease manifestations of DMD [6][7] Market Data and Key Metrics Changes - The FDA has accepted the BLA for review with a target action date of August 22, 2026, marking a significant regulatory milestone for the company [5][17] - The company is preparing for a potential commercial launch and has completed its FDA pre-license inspection for its manufacturing facility [18][19] Company Strategy and Development Direction - The company is building an infrastructure to support the launch and commercialization of Deramiocel while expanding its pipeline to treat other indications [8][20] - The company is also exploring potential expansion into other diseases, initially focusing on Becker muscular dystrophy [21] - The company is committed to maintaining a disciplined approach to execution and investing in its pipeline to operate as a world-class commercial biotech company [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the data supporting Deramiocel and its potential to become a foundational therapy for DMD [16][24] - The company believes it is well-positioned for growth, with a strong balance sheet and operational readiness for commercial launch [8][25] - Management highlighted the importance of addressing the unmet need in the DMD community and the urgency to provide Deramiocel to patients [19][70] Other Important Information - The company completed a public offering in December 2025, resulting in net proceeds of approximately $162 million, which strengthens its financial position [26] - The company is also working on its exosome platform, with ongoing studies related to a COVID vaccine and plans for future therapeutic applications [22][101] Q&A Session Summary Question: Anticipation of Ad Com and Commercial Preparation - Management indicated that there has been no movement towards an Advisory Committee meeting at this point, and they are preparing for commercial readiness regardless [33][34] Question: Labeling Discussions and Expectations - Management noted that they have not had detailed labeling discussions yet but believe the data supports a label for both DMD and cardiomyopathy [36][52] Question: Cohorts in HOPE-3 Trial - Management clarified that the FDA considers the two cohorts of the HOPE-3 trial as one clinical trial, and both cohorts showed statistically significant results [44] Question: Transition of Clinical Trial Patients to Commercial Drug - Management confirmed that they expect to transition all clinical trial patients to the commercial drug and are planning for market access to facilitate this [67][70] Question: Early Intervention and Labeling - Management emphasized the importance of early intervention and is focusing on younger patients, although obtaining a prevention label is challenging [76] Question: Manufacturing Capacity and Expansion Plans - Management is actively planning to expand manufacturing capabilities to accommodate more patients as needed [70][71]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents and marketable securities totaled approximately $318.1 million, up from approximately $151.5 million as of December 31, 2024 [24] - Revenue for Q4 2025 was $0, compared to approximately $11.1 million for Q4 2024, and for the full year 2025, revenue was also $0, down from approximately $22.3 million in 2024 [24] - Total operating expenses for Q4 2025 were approximately $29.2 million, compared to approximately $18.8 million for Q4 2024, with full-year operating expenses at approximately $108.1 million, up from approximately $64.8 million in 2024 [25] - Net loss for Q4 2025 was approximately $30.2 million, compared to a net loss of approximately $7.1 million for Q4 2024, and for the full year 2025, the net loss was approximately $105 million, compared to approximately $40.5 million in 2024 [26] Business Line Data and Key Metrics Changes - The company is focused on advancing Deramiocel for Duchenne muscular dystrophy (DMD), with a Biologics License Application (BLA) under review by the FDA [4][5] - The HOPE-3 trial showed significant results, including a 91% slowing of disease progression in left ventricular ejection fraction among evaluable patients [7][8] - The company aims to position Deramiocel to treat as many eligible patients as possible, with a focus on both skeletal and cardiac disease manifestations of DMD [5][6] Market Data and Key Metrics Changes - The FDA has accepted the BLA for review with a target action date of August 22, 2026, marking a significant regulatory milestone for the company [4][15] - The company is preparing for a potential commercial launch and has completed its FDA pre-license inspection for its manufacturing facility [16][17] Company Strategy and Development Direction - The company is building an infrastructure to support the launch and commercialization of Deramiocel while expanding its pipeline to treat other indications [6][19] - The company is also exploring expansion into other diseases, initially focusing on Becker muscular dystrophy [19] - The company is committed to maintaining a disciplined approach to execution and investing in its pipeline to operate as a world-class commercial biotech company [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the data and the company's manufacturing readiness, positioning it well for growth [6][15] - The company is focused on addressing the unmet needs of the DMD community and is preparing for a potential commercial launch [17][18] - Management highlighted the importance of the HOPE-3 trial data in supporting the therapeutic profile of Deramiocel [14][15] Other Important Information - The company ended 2025 with a strong cash position of approximately $318 million, which is expected to fund operations into the fourth quarter of 2027 [22] - The company has been approved for uplisting to the Nasdaq Global Select Market, enhancing visibility within the institutional investment community [23] Q&A Session Summary Question: Anticipation of Ad Com and commercial preparation for Deramiocel approval - Management indicated that there has been no movement towards an Advisory Committee meeting and expressed confidence in the strength of the HOPE-3 data regardless of the review process [30][32] Question: Clarification on the label for Deramiocel - Management believes the data supports a label for both DMD and cardiomyopathy, with ongoing discussions with the FDA [34][35] Question: Status of the two cohorts in the HOPE-3 trial - Management confirmed that the FDA considers the two cohorts as one trial and expressed confidence in the statistical significance of cohort B [39][41] Question: Expectations for the peer-reviewed publication of HOPE-3 data - Management stated that the academic review process is ongoing and updates will be provided once the publication is ready [42] Question: Insights from the Muscular Dystrophy Association meeting - Management noted that the HOPE-3 data has solidified belief in Deramiocel among physicians and increased inquiries about prescribing and availability [60] Question: Plans for scaling manufacturing capacity - Management confirmed plans for additional manufacturing build-out to accommodate more patients, contingent on the successful response to the BLA [66][67]

Core Insights - Cellectis will report its financial results for Q4 and full year 2025 on March 19, 2026, after the US market closes [1] - An investor conference call and webcast will take place on March 20, 2026, at 8:00 AM ET, to discuss the financial results and business updates [2] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using a pioneering gene-editing platform [3] - The company employs an allogeneic approach for CAR T immunotherapies, aiming to provide off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment [3] - Cellectis has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that control the entire cell and gene therapy value chain [3] Company Locations and Listings - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [4] - The company is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS [4]

Core Viewpoint - Elicio Therapeutics is making significant progress in developing its lead immunotherapy candidate, ELI-002 7P, for treating KRAS-mutant pancreatic cancer, with an event-driven primary disease-free survival analysis expected in the first half of 2026 [2][5][12] Financial Performance - In 2025, the company reported a net loss of $39.5 million, a decrease from $51.9 million in 2024, with a net loss per share of $2.58 compared to $4.25 in the previous year [8][11] - Research and development (R&D) expenses for 2025 were $24.9 million, down from $33.7 million in 2024, primarily due to lower clinical costs as patients progressed into the observation phase of the Phase 2 study [7][11] - General and administrative (G&A) expenses increased to $12.8 million in 2025 from $11.3 million in 2024 [7][11] - Cash and cash equivalents as of December 31, 2025, were $18.6 million, compared to $17.6 million at the end of 2024, with projected cash runway extending into Q3 2026 [8][9][14] Clinical Development - The Phase 2 AMPLIFY-7P trial is ongoing, with fewer disease progressions and deaths observed than projected, reinforcing confidence in ELI-002 7P's potential [2][5][6] - Evidence of antigen spreading to patient-specific neoantigens beyond mKRAS has been reported, indicating the potential durability of the immune response [6] - The company plans to request an End-of-Phase 2 meeting with the FDA to finalize the Phase 3 trial design for ELI-002 7P following the primary DFS analysis [12] Upcoming Milestones - The event-driven primary DFS analysis for the Phase 2 AMPLIFY-7P study is anticipated in the first half of 2026 [5][6] - Elicio will present updates on the ELI-002 platform and AMPLIFY-7P trial at upcoming conferences, including the World Vaccine Congress and the AACR Annual Meeting [6]

Core Insights - Kura Oncology is participating in a fireside chat hosted by Barclays, indicating engagement with investors and analysts in the biotech sector [1] Company Overview - Troy Wilson serves as the President and Chief Executive Officer of Kura Oncology, while Brian Powl holds the position of Chief Commercial Officer [1]

Core Insights - Allogene Therapeutics is at a critical juncture with the upcoming interim data from the ALPHA3 trial of cema-cel, which aims to determine if early, MRD-guided allogeneic CAR T therapy can prevent relapse in large B-cell lymphoma (LBCL) [2][3] - The company is focused on demonstrating that allogeneic CAR T can be delivered at a biologic-like scale, moving beyond academic settings [2][4] - Allogene has a cash runway extending into Q1 2028, allowing for disciplined execution and data delivery across its portfolio [2][13] Company Updates - The ALPHA3 trial is designed to evaluate cema-cel as a "7th cycle" of first-line therapy, integrating it without altering existing treatment workflows [4] - The trial is enrolling patients at over 60 clinical sites, including both academic and community cancer centers, to enhance patient access [4] - An interim futility analysis is scheduled for April 2026, which will compare MRD clearance rates between cema-cel and observation [5] Product Development - ALLO-329 is a next-generation allogeneic CAR T therapy targeting CD19/CD70, utilizing proprietary Dagger technology for built-in lymphodepletion [6][10] - The Phase 1 RESOLUTION trial for ALLO-329 is currently enrolling patients across multiple autoimmune indications, with proof-of-concept data expected in June 2026 [7][10] - ALLO-316 has shown significant response rates in metastatic solid tumors, with the TRAVERSE trial completed and the company exploring partnership opportunities [11] Financial Performance - As of December 31, 2025, Allogene reported $258.3 million in cash, cash equivalents, and investments, extending its cash runway into Q1 2028 [12][13] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [16] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, with a full-year net loss of $190.9 million, or $0.87 per share [16][22]

Core Insights - Capricor Therapeutics is advancing its lead product candidate, Deramiocel, for Duchenne muscular dystrophy (DMD) with a Biologics License Application (BLA) currently under FDA review, targeting a decision date of August 22, 2026 [2][5] - The company reported significant financial results for the fourth quarter and full year of 2025, including a cash balance of approximately $318 million, which is expected to support operations through 2027 [7][11] Regulatory and Clinical Updates - The FDA is reviewing Capricor's BLA for Deramiocel, classified as a Class 2 resubmission, with the company focusing on execution and preparation for a potential launch [5][6] - The pivotal HOPE-3 Phase 3 trial met its primary endpoint and key secondary cardiac endpoint, demonstrating statistical significance [4][5] - Late-breaking data from the HOPE-3 trial presented at the 2026 MDA Conference highlighted Deramiocel's benefits on cardiac function and disease progression [4][5] Financial Performance - Capricor reported no revenues for the fourth quarter and full year of 2025, a decrease from $11.1 million and $22.3 million in the respective periods of 2024 [8] - Total operating expenses for Q4 2025 were approximately $29.2 million, up from $18.8 million in Q4 2024, with total operating expenses for the year reaching approximately $108.1 million [9] - The net loss for Q4 2025 was approximately $30.2 million, or $0.62 per share, compared to a net loss of $7.1 million, or $0.16 per share, in Q4 2024 [10] Corporate Developments - Capricor's GMP manufacturing facility in San Diego is operational and has completed an FDA Pre-License Inspection, positioning the company for a potential commercial launch [6][4] - The company successfully uplisted to the Nasdaq Global Select Market, enhancing its visibility and access to capital [4][14] - Capricor's balance sheet was strengthened by a public offering that generated approximately $161.9 million in net proceeds [14][7]

Company Overview - 4D Molecular Therapeutics is a next-generation gene therapy company founded approximately 12 years ago, focusing on developing tissue-specific vectors and capsids through a platform called directed evolution [2] - The company aims to deliver safer doses and target larger market therapeutic areas rather than just rare diseases, which is common in many gene therapies [2] Lead Program - The lead program of the company is 4D-150, which is currently progressing through Phase III trials [3] - This program targets retinal diseases, with lead indications for wet age-related macular degeneration and plans to initiate a Phase III trial for diabetic macular edema in the future [3]

Company Overview - Protagonist Therapeutics focuses on innovation through novel peptides, specializing in both injectable and oral peptides, with a history dating back to 2008 [3] - The company went public in 2016, with Barclays as one of the banks that facilitated the IPO [2] Recent Developments - Protagonist has two significant assets that demonstrated outstanding Phase III data last year, indicating progress in their clinical development [4]